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Abstract
Connective tissue growth factor (CTGF/CCN2) is an angiogenetic and profibrotic factor, acting downstream of TGF-b,
involved in both airway- and vascular remodeling. While the T-helper 1 (Th1) cytokine interferon-gamma (IFN-c) is well
characterized as immune-modulatory and anti-fibrotic cytokine, the role of IFN-c in lung endothelial cells (LEC) is less
defined. Tumour necrosis factor alpha (TNF-a) is another mediator that drives vascular remodeling in inflammation by
influencing CTGF expression. In the present study we investigated the influence of IFN-c and TNF-a on CTGF expression in
human LEC (HPMEC-ST1.6R) and the effect of CTGF knock down on human LEC. IFN-c and TNF-a down-regulated CTGF in
human LEC at the promoter-, transcriptional- and translational-level in a dose- and time-dependent manner. The inhibitory
effect of IFN-c on CTGF-expression could be almost completely compensated by the Jak inhibitor AG-490, showing the
involvement of the Jak-Stat signaling pathway. Besides the inhibitory effect of IFN-c and TNF-a alone on CTGF expression
and LEC proliferation, these cytokines had an additive inhibitory effect on proliferation as well as on CTGF expression when
administered together. To study the functional role of CTGF in LEC, endogenous CTGF expression was down-regulated by
a lentiviral system. CTGF silencing in LEC by transduction of CTGF shRNA reduced cell proliferation, but did not influence the
anti-proliferative effect of IFN-c and TNF-a. In conclusion, our data demonstrated that CTGF was negatively regulated by
IFN-c in LEC in a Jak/Stat signaling pathway-dependent manner. In addition, an additive effect of IFN-c and TNF-a on
inhibition of CTGF expression and cell proliferation could be found. The inverse correlation between IFN-c and CTGF
expression in LEC could mean that screwing the Th2 response to a Th1 response with an additional IFN-c production might
be beneficial to avoid airway remodeling in asthma.
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Introduction
Although asthma is considered to be an entirely reversible
disorder, patients with asthma experience an accelerated rate of
deterioration of the respiratory function [1]. This deterioration is
clinically characterised by irreversible or only partially reversible
airway obstruction and persistent airway hyperresponsiveness.
Recently, attention has been focused on the structural changes in
the airways, collectively referred to as airway remodeling. These
changes include thickening of the basement membrane, airway
smooth muscle (ASM) hypertrophy and/or hyperplasia, alterations
in the composition of the extracellular matrix (ECM), lung
fibroblast proliferation and vascular remodeling [2]. The last one,
including angiogenesis, vasodilatation, and microvascular leakage,
is one of the most prominent and uniform findings in asthma [2].
Compared with control subjects, the total number of vessels and
vascular areas in the airways are increased in asthmatics [3]. This
increased number and size of vessels and the vascular leakage
contribute to the thickening of the airway wall, resulting in
a narrowing of the lumen. In addition, individuals with stable
asthma have shown increased levels of circulating bone marrow-
derived endothelial progenitor cells (EPC) in their blood [4].
TGF-b is one of the critical mediators in the pathogenesis of
asthma, involved in the regulation of both airway inflammation
and airway/vascular remodeling [5]. Increased TGF-b levels were
detected in asthmatic bronchoalveolar lavage fluids [6]. TGF-
b acts as suppressive cytokine that prevents lymphocyte activation
and mediates peripheral tolerance toward allergens [5]. In
addition, TGF-b assists during wound repair inducing ECM
deposition, and thus is critically contributing to lung fibrosis [5].
Furthermore, dysregulation of TGF-b is associated with an
increasing number of vascular pathologies [7]. Downstream of
TGF-b, connective tissue growth factor (CTGF) modulates the
cellular response to TGF-b and contributes to wound healing and
fibrotic response [8]. Furthermore, CTGF regulates angiogenesis
and endothelial cell function, especially by facilitating the
angiogenetic response that supports tissue repair [9]. The role of
CTGF in airway remodeling in asthma has not been elucidated in
detail, but CTGF has the potential to be a key factor in the
development and maintenance of the structural changes associated
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with severe persistent asthma due to its simultaneous angiogenic
and fibrogenic properties [10–12].
The role of the Th1 cytokine IFN-c in asthma is controversial.
On the one hand, the level of IFN-c was decreased in asthma
[13,14] and the potential use of IFN-c in allergic diseases has been
suggested in a number of human and animal studies [15–18]. Loss
of IFN-c action, therefore, was suggested to contribute to the
altered immune state characterising asthma. On the other hand,
elevated IFN-c has been also identified in asthmatic patients,
suggesting that Th1-like cells may also contribute to, rather than
inhibit, the asthma physiopathology [19,20]. Furthermore, in an
allergen-challenge asthma model, bone marrow-derived endothe-
lial progenitor cells (EPC) recruitment was Th1 and Th2
dependent and associated with increased microvessel density [4].
In addition, both Th1 and Th2 cytokines can modulate neo-
vascularization by controlling EC function, including migration,
invasion, proliferation, and apoptosis, all of which are crucial for
the formation of new blood vessels [21,22]. This observation is in
agreement with the hypothesis that the Th1/Th2 paradigm could
be much more complex than what was initially appreciated [23].
The Th1/Th2 paradigm suggested that Th1 and Th2 cells
counterbalance each other and that Th1 cells protect or prevent
Th2-mediated allergic disease and asthma [24]. However, antigen
specific Th1 cells were ineffective in reducing airway hyperreac-
tivity induced by Th2 cells and caused serious airway inflamma-
tion [23]. The possible role and mechanisms of IFN-c-induced
vascular remodelling in lung endothelial cells (LEC) have not been
adequately defined yet.
The IFN-c-induced Stat-signalling pathway is well characterised
[25]: IFN-c binds to its receptor (IFN-cR) and leads to the
aggregation of a- and b-chains, constitutively associated with
Janus Kinases (JAKs). Once activated, JAKs phosphorylate the
IFN-cRa chain creating a docking site for Stat1, which is then
phosphorylated and associated in homodimers. The p-Stat1
homodimer translocates to the nucleus where it is able to bind
to specific DNA sequences. Stat1 phosphorylation is necessary for
Stat1 dimerization, nuclear translocation, and DNA binding [25].
TNF-a is another cytokine involved in inflammation, triggering
vascular remodeling processes [26]. Increased expression of TNF-
a was reported in severe and refractory asthma [27,28] and TNF-
a can inhibit CTGF expression [29–31].
The current study was designed to address the question of
whether the anti-fibrotic and angiostatic cytokine IFN-c was
capable to modulate CTGF production in airway endothelial cells
and how this potential regulation is influenced by TNF-a. In
addition, the signaling mechanisms by which IFN-c modulates
CTGF production and the effects of CTGF gene silencing on LEC
were explored.
Methods
Reagents
Recombinant TGF-b1, TNF-a, and IFN-c were obtained from
R&D Systems (Abingdon, UK). The Jak-Inhibitor (AG-490) was
obtained from Calbiochem (658411; La Jolla, CA, USA), rCTGF
from Biovendor (Heidelberg, Germany). The Cell Proliferation
ELISA (BrdU, chemiluminescent) and protease inhibitor cocktail
tablets were provided by Roche (Mannheim, Germany).
Cell Culture
HPMEC-ST1.6R, a human LEC line, has already been
described and exhibited a broad spectrum of primary human
microvascular endothelial cell characteristics in vitro [32,33]. Cells
were grown on plastic tissue culture dishes in RPMI medium
containing 10% fetal bovine serum (experiments with TGF-b1
were done in serum-free medium), penicillin (100 U/ml), strepto-
mycin (100 mg/ml), and amphotericin B (0.25 mg/ml). On 6-cm
dishes, cells were allowed to grow until 80% confluence before
adding the investigated agents. Incubation was carried out at 37uC
in a humidified atmosphere of 95% room air and 5% CO2.
HPMEC-ST1.6R cells were used in experiments between passage
number 3 and 34. HEK 293 T cells, human embryonic kidney
cells, were obtained from ATCC (Manassas, USA). Cells were
cultured in DMEM Ham`s F12 medium with L-Glutamin,
containing 10% fetal bovine serum, 1% penicillin (100 U/ml)
and streptomycin (100 mg/ml).
Viability Detection
HPMEC-ST1.6R cell viability after exposure to TGF-b1
(10 ng/ml), TNF-a (20 ng/ml), IFN-c (500 U/ml), rCTGF
(200 ng/ml), or the Jak-inhibitor AG-490 (30 mM) was evaluated
after 1–3 days using the flow cytometry–based quantification of
ethidium bromide (1 mmol/L; Sigma Aldrich) uptake.
Proliferation Assay
To monitor DNA synthesis, HPMEC-ST1.6R cells were seeded
in 24-well plates (Costar, Corning, NY) and allowed to attach for
24 h, followed by serum starvation for 24 h (experiments with
TGF-b1). Cells (triplicates) were then incubated with rCTGF,
IFN-c, TNF-a, TGF-b1 alone or in combination at different time
points with the simultaneous addition of BrdU. For the analysis of
cell proliferation the chemiluminescent BrdU ELISA kit from
Roche was used according to the manufacturer’s protocol. The
signals were visualised and evaluated on a LumiImager work
station using image analysis software (Boehringer, Mannheim,
Germany).
Transfections and Reporter Gene Assays
Cloning of the CTGF promoter (pCT-sb)-Luciferase plasmid
has already been described elsewhere [34]. pCT-sb (2 mg) and
Renilla luciferase control reporter vector (phRL-TK; 5 ng) were
transfected with LipofectaminPlus (Invitrogen) into HPMEC-
ST1.6R and seeded into 6-well plates. Transfection medium
(Optimem-medium, Invitrogen) was changed to 0.2% fetal bovine
serum after 2 hours. Twenty-four hours after transfection, cells
were treated with indicated molecules. After 16 hours, luciferase
activity was measured by the dual luciferase assay system (Promega
Biotech Inc., Madison, Wis) according to the manufacturer’s
instruction using a Berthold MiniLumat LB 9506 luminometer
(Bad Wildbach, Germany). Firefly luciferase activity was normal-
ised by the activity of Renilla luciferase under the control of
thymidine kinase promoter of phRL-TK. Results are given as
relative light units. All values were obtained from experiments
carried out in triplicates and repeated at least 3 times.
RNA Extraction and Reverse Transcription
Total RNA was isolated from HPMEC-ST1.6R cells using the
RNeasy mini kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. The RNA was eluted in 40 mL water and
subjected to reverse transcription. Purity and yield of the RNA
were photometrically determined. Overall, 5 mg total RNA was
reverse transcribed by addition of 500 mg/mL oligo (dT)12
primers (Roche, Basel, Switzerland), RNAse Inhibitor (10 U/mL,
Roche), dNTP (5 mmol/L each dNTP; Qiagen), and Omniscript
transcriptase (Qiagen) (0.2 U/mL) for 1 hour at 37uC. The cDNA
was denatured at 90uC for 5 minutes and used for PCR
amplification.
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Real-time PCR Analysis
The CTGF or b-actin quantitative real-time PCR (TaqManTM)
primers and probes were obtained from Applied Biosystems
(Weiterstadt, Germany). All PCRs were performed utilizing 1 mg/
ml cDNA per reaction in dublicates of 30 ml volume on an ABI
Prism 7300 Sequence Detection System (TaqMan), using a 2-step
PCR protocol after initial denaturing of the DNA (10 min at 95uC)
with 40 cycles of 95uC for 15 s and 60uC for 1 min. A universal
master mix, obtained from Applied Biosystems, included all
reagents as Taq-polymerase and buffer apart from specific primers
and probes. All amplification batches included no template
controls. Neither negative controls nor mRNA probes led to
elevated fluorescence signals after PCR. Dilution experiments
were performed to ensure similar efficiency of the PCRs, and
standard curves were calculated referring the threshold cycle to the
log of each cDNA dilution step. Results of CTGF or transgelin
were normalized to b-actin and mean fold changes in mRNA
expression were calculated by the DDCt-method [35].
Western Blot Analysis
HPMEC-ST1.6R cells were rinsed with ice-cold tris-buffered
saline (TBS) and incubated in 100 ml lysis buffer (Cell lysis buffer,
Cell Signaling Technologies, MA, USA, Complete Mini protease
inhibitor cocktail tablets and PhosStop phosphatase inhibitor
cocktail tablets (Roche, Germany; 0.1 mM PMSF, Merck KGaA,
Germany)) for 10 minutes on ice. The lysate was cleared by
centrifugation with 30,000 g for 10 min, and the supernatant was
used for Western immunoblotting analysis. Protein concentrations
were determined for each sample using the Bradford assay (Bio-
Rad, Richmond, CA, USA) and equal amounts of cellular protein
were loaded and separated by SDS-PAGE on 10% to 12% Bis-
Tris gels and electrophoretically transferred to polyvinylidene
difluoride or nitrocellulose blotting membranes (Amersham
Pharmacia Biotech, Piscataway, NJ, USA). Membranes were
blocked in 5% BSA for 1 hour at room temperature and
successively incubated with primary antibodies overnight at 4uC.
Western blots were probed with primary antibodies to b-actin,
CTGF (Santa Cruz Biotechnology, CA, USA), Stat-1, phospho-
Stat1 (Tyr705, Cell Signaling Technologies, MA, USA), and TGF-
ß1 (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany and
Sigma-Aldrich Chemie GmbH, Steinheim, Germany) followed by
the corresponding horseradish peroxidase-conjugated secondary
antibody (Pierce, Bonn, Germany) for 1 h at room temperature.
Specific protein bands were visualised using enhanced chemilu-
minescence (SuperSignal West Dura, Pierce Inc., Rockford, USA;
GE Healthcare Europe GmbH, Mu¨nchen, Germany) and
detected using the LAS 3000 computer-based luminescent image
analyzer (FujiFilm, Tokyo, Japan). Accumulated signals were
analyzed using AIDA software (Raytest, Germany).
CTGF Gene Silencing by Lentiviral Transduction
For the downregulation of endogenous CTGF expression in
HPMEC-ST1.6R, a lentiviral system (psPAX2, pMD2G, Addgene
Inc., Cambridge, USA) with a set of different shRNAs (Open
Biosystems, Inc., Fisher Scientific GmbH, Schwerte, Germany)
was used. Scrambled shRNA, vector only (Addgene Inc., Cam-
bridge, USA), and GFP (Sigma-Aldrich Chemie GmbH, Stein-
heim, Germany) were used for controls. The first day 66105 HEK
293T cells (ATCC, Manassas, USA) were seeded per 6-well in
DMEM/Hams F12 cell culture medium (PAA Laboratories,
Pasching, Austria) containing 10% FCS (PAA) and 0,1%
Penicillin/Streptomycin (PAA). After 24 h of incubation the cells
reached about 80% confluency and were transfected. Lipofecta-
min 2000TM transfection reagent (Invitrogen GmbH, Darmstadt,
Germany) and DMEM/Hams F12 medium, without additives,
where then mixed and incubated for 5 minutes at room
temperature. In the next step, psPAX2, pMD2.G and shRNA
respectively scrambled, vector only and GFP plasmid were mixed
and given to the Lipofectamin 2000TM/DMEM Hams F12
mixture. After 20 minutes of incubation at room temperature,
HEK 293 T cells were transfected by this mixture and incubated
for 18 h at 37uC. On day three, medium was changed with
DMEM Hams F12 containing 30% FCS and 1% Penicillin/
Streptomycin, incubated for further 24 h at 37uC, and then
replaced with normal growth medium. 16105 HPMEC-ST1.6R
cells were seeded per 6-well for later transduction. The next day,
the virus supernatant of the HEK 293T cells was centrifuged and
given, together with Polybrene (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany), to the target cells. The transduced target
cells were incubated for further 24 h at 37uC and then medium
was replaced with normal growth medium. Two to three days after
lentiviral transduction the effect could be observed under UV light
by green fluorescing GFP control.
Statistical Analysis
All results shown are representative of three separate
experiments. Results are given as means 6 SEM. Data were
analyzed by the Mann-Whitney-Wilcoxon test. A p-value ,0.05
was considered significant. All statistical analyses were per-
formed using the statistical software GraphPad Prism 5.0.
Results
Effect of CTGF on LEC Proliferation
To investigate the influence of CTGF to the proliferative
behaviour of LEC, the effect of rCTGF on the in vitro proliferation
of human LEC was analysed. CTGF induced LEC proliferation in
a dose-dependent manner (Figure 1A). The highest increase in
proliferation (2.6-fold) was measured with a concentration of
100 ng/ml of rCTGF. There was no difference of cell proliferation
in LEC treated with 100 ng/ml rCTGF between different time
points (12 h–72 h; Figure 1B).
Regulation of CTGF Expression by IFN-c in LEC
We examined the effect of IFN-c on CTGF promoter activity in
LEC. IFN-c significantly reduced CTGF promoter activity in
a dose dependent manner (Figure 2A). The maximum inhibition
of luciferase activity was a 2.2-fold reduction with 500 U/ml IFN-
c. IFN-c decreased CTGF mRNA expression in a dose-dependent
(Figure 2B) and time-dependent (Figure 2C) manner at the
transcriptional-level. A maximum inhibition of CTGF mRNA by
IFN-c was observed after 12 h (2.5-fold inhibition). At the
translation-level, IFN-c decreased CTGF protein expression in
LEC in a dose- (Figure 2D) and time-dependent manner
(Figure 2E) with a maximal inhibition after 48 h with an IFN-c
concentration of 500 U/ml. These results indicated that IFN-c
down-regulated CTGF at the promoter-, transcriptional- and
translation-level in LEC.
Down-regulation of CTGF by IFN-c is Mediated by Jak/
Stat Signaling Pathway
In the next step we wanted to demonstrate that IFN-c can
activate Jak-Stat signaling in LEC. Phosphorylation of Stat1 was
detected 1 min after addition of IFN-c and further enhanced up to
5 min (Figure 3A). This effect of IFN-c on Stat1 phosphorylation
was dose-dependent, with a maximal effect at a concentration of
500 U/ml (Figure 3B), and could be inhibited by the Jak inhibitor
AG-490 (Figure 3C). These results demonstrated that IFN-c can
CTGF Gene Regulation in Lung Endothelial Cells
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induce Jak-Stat signaling in LEC, which could be blocked by the
Jak-inhibitor AG-490.
In an attempt to define the role of the Jak/Stat signaling
pathway in the down-regulation of CTGF by IFN-c, we treated
LEC with IFN-c in the presence or absence of the Jak inhibitor
AG-490, and analysed CTGF-promoter activity, -mRNA, and -
protein expression. With all the three different methods, luciferase-
Assay (Figure 3D), real-time quantitative PCR assay (Figure 3E),
and western immunoblotting assay (Figure 3F), the inhibition of
CTGF expression by IFN-c in LEC could be partially blocked by
Figure 1. Effect of rCTGF on proliferation of LEC. A. Proliferation in LEC was assessed 3 days after the addition of rCTGF at the indicated
concentration. B. Proliferation in LEC was assessed after the addition of 100 ng/ml CTGF at the indicated time points. Values are means 6 SEMs for 3
replicate experiments. Significant differences (p,0.05) compared with untreated cells are marked by *. RLU/s (relative light unit/second).
doi:10.1371/journal.pone.0045430.g001
Figure 2. Effect of IFN-c on CTGF expression in LEC. A. Luminometric analysis of CTGF-Luc reporter transfected LEC: LEC were incubated with
medium alone (control) or with decreasing concentrations of IFN-c. * p,0.05 vs medium alone. B+C. CTGF mRNA expression: LEC were incubated
with different concentrations of IFN-c for 12 h (B) or with IFN-c (500 U/ml) for various duration (C). mRNA expression of CTGF normalized for b-actin
were measured by real-time PCR. Significant differences (p,0.05) compared with untreated cells are marked by *. D+E. CTGF protein expression: LEC
were incubated with different concentrations of IFN-c (D) and for different time points (E). CTGF and b-actin expression was detected by
immunoblotting. A representative of 3 independent experiments is shown.
doi:10.1371/journal.pone.0045430.g002
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the Jak inhibitor AG-490. These results demonstrated that the Jak-
Stat signaling pathway was involved in the inhibitory effect of IFN-
c on CTGF-expression.
Regulation of CTGF Expression by TNF-a in LEC
At the next step we examined the effect of TNF-a on CTGF
expression in LEC. At the promoter level, TNF-a inhibited
CTGF-promoter activity in LEC in a dose dependent manner
(Figure 4A). At a concentration of 20 ng/ml, TNF-a reduced
CTGF-promoter activity 2.5-fold compared to untreated cells. At
the transcriptional- and translational-levels we found a dose- and
time-dependent reduction of CTGF mRNA with a maximal 2.5-
fold inhibition after 24 h at a concentration of 20 ng/ml
(Figure 4B+C) and of CTGF protein expression with a maximal
decrease with 20 ng/ml TNF-a after 48 h (Figure 4D+E). Taken
together, these data showed that TNF-a inhibited CTGF
expression in LEC.
Additive Effect of IFN-c and TNF-a on CTGF Inhibition
In subsequent experiments we studied whether there was an
additive effect of IFN-c and TNF-a on the inhibition of CTGF
expression in LEC. An additive effect on CTGF inhibition after
the co-administration of IFN-c and TNF-a could be detected on
CTGF promoter activity (Figure 5A), on CTGF mRNA expres-
sion (Figure 5B), and on CTGF protein expression (Figure 5C).
These results indicated that besides the inhibitory effect of IFN-c
and TNF-a alone, both cytokines had an additive effect on
inhibition of CTGF expression in LEC when administered
together.
Additive Effect of IFN-c and TNF-a on the Inhibition of
LEC Proliferation
To investigate whether IFN-c and TNF-a influenced the
proliferative behaviour of LEC, the effect of IFN-c and/or
TNF-a on in vitro proliferation of human LEC was analysed
(Figure 6A–C). Both TNF-a and IFN-c reduced LEC pro-
liferation in a dose-dependent manner. At the highest concen-
tration tested, TNF-a (20 ng/mL) reduced proliferation of LEC
to 43% (Figure 6A) and IFN-c (500 U/ml) to 64% (Figure 6B).
IFN-c (500 U/ml) and TNF-a (20 ng/ml) co-operatively in-
hibited LEC proliferation below the levels of IFN-c and TNF-
a alone (16% versus 43% and 64%; Figure 6C). Compared
with medium, IFN-c and/or TNF-a had no influence on the
percentage of viable LEC (data not shown). In summary, these
results showed an additive effect of IFN-c and TNF-a on
inhibition of LEC proliferation.
Figure 3. Effect of the Jak1-inhibitor AG-490 on IFN-c induced inhibition of CTGF expression in LEC. LEC were incubated for different
time points with 500 U/ml IFN-c (A), with different concentrations of INF-c for 5 min (B), or with or without the Jak-inhibitor AG-490 (30 mM) and INF-
c (500 U/ml) for 5 min (C). Stat1 phosphorylation and Stat1 expression were detected by immunoblotting with anti-phospho-Stat1 and anti-Stat1
antibodies. A representative of 3 independent experiments is shown. D. Luminometric analysis of CTGF-Luc reporter transfected LEC: LEC were
incubated with medium alone (control) or with IFN-c without or with the Jak-inhibitor AG-490 (30 mM). * p,0.05 vs. medium alone;# p,0.05 vs IFN-
c alone. E+F. LEC were incubated with IFN-c with or without the Jak-inhibitor AG-490 (30 mM). CTGF mRNA expression compared to b-actin was
measured by real-time PCR (E). CTGF and b-actin protein expression was determined by immunoblotting (F). Significant differences (p,0.05)
compared with untreated cells are marked by *, compared with IFN-c are marked with #. A representative of 3 independent experiments is shown
(F).
doi:10.1371/journal.pone.0045430.g003
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CTGF Silencing with shRNA in LEC
To study the functional role of reduced CTGF expression in
LEC, we generated lentiviral vector carrying CTGF-specific
silencing shRNA. Stable transfection of LEC CTGF shRNA
resulted in a decrease of CTGF mRNA basal level of up to 75%
(Figure 7A) as well as of the protein level (Figure 7B) compared
with non-specific scrambled control cells. The known induction of
CTGF mRNA after TGF-b1 treatment was also inhibited by the
CTGF shRNA (Figure 7A). Similar results were observed at the
protein level for TGF-b1-induced CTGF expression (Figure 7B).
These results demonstrated that production of CTGF in LEC was
significantly knocked down by CTGF shRNA.
Effect of CTGF Silencing on the Proliferation of LEC and
the Inhibitory Effect of IFN-c and TNF-a
Down-regulation of CTGF by shRNA transfection reduced the
proliferation of HPMEC cells by 96% compared with non-specific
scrambled control shRNA cells (Figure 8A). Furthermore, rCTGF-
induced LEC proliferation was also reduced by the CTGF shRNA
(1.7-fold increase) compared with non-specific scrambled control
Figure 4. Effect of TNF-a on CTGF expression in LEC. A. Luminometric analysis of CTGF-Luc reporter transfected LEC: LEC were incubated with
medium alone (control) or with decreasing concentrations of TNF-a. * p,0.05 vs medium alone. B+C. CTGF mRNA expression: LEC were incubated
with different concentrations of TNF-a for 24 h (B) or for various duration with 20 ng/ml TNF-a (C). mRNA expression of CTGF normalized for b-actin
were measured by real-time PCR. Significant differences (p,0.05) compared with untreated cells are marked by *. D+E. CTGF protein expression: LEC
were incubated with different concentrations of TNF-a for 48 h (D) or with TNF-a (20 ng/ml) for different time periods (E). CTGF and b-actin
expression was detected by immunoblotting. A representative of 3 independent experiments is shown.
doi:10.1371/journal.pone.0045430.g004
Figure 5. Additive effect of IFN-c and TNF-a on the inhibition of CTGF expression. A. Luminometric analysis of CTGF-Luc reporter
transfected HPMEC cells: LEC were incubated with medium alone (control), TNF-a, IFN-c, or INF-c and TNF-a. * p,0.05 vs medium alone;# p,0.05 vs
INF-c or TNF-a alone. B+C. LEC were incubated with TNF-a and/or IFN-c. CTGF mRNA expression compared to b-actin was measured by real-time PCR
(B). CTGF and b-actin protein expression was determined by immunoblotting (C). Significant differences (p,0.05) compared with untreated cells are
marked by *, compared with INF-c or TNF-a are marked with #. A representative of 3 independent experiments is shown (C).
doi:10.1371/journal.pone.0045430.g005
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shRNA cells (2.6-fold increase) (Figure 8A). IFN-c could antag-
onize CTGF-induced proliferation both in control and CTGF
shRNA cells (Figure 8A).
In addition, we analysed the inhibitory effect of IFN-c on the
proliferation of CTGF-deficient LEC. No significant difference in
IFN-c-, TNF-a-, and combination of IFN-c- and TNF-a-mediated
proliferation inhibition was observed between control and CTGF
shRNA cells. (Figure 8B). These results demonstrated that the
inhibitory effect of IFN-c and TNF-a on LEC proliferation was
not mediated by down-regulation of CTGF.
Discussion
IFN-c is a well characterised immuno-modulatory and anti-
fibrotic cytokine, whereas the role of IFN-c in lung endothelial cell
biology is less defined. The present study provided evidence that
CTGF was negatively regulated by IFN-c in LEC in a Jak/Stat
signaling pathway-dependent manner. In addition, an additive
effect of IFN-c and TNF-a on inhibition of CTGF expression and
cell proliferation could be found. CTGF silencing in LEC by
transfection of CTGF shRNA reduced cell proliferation. However,
CTGF silencing had no effect on IFN-c and TNF-a mediated
inhibition of LEC proliferation.
Evidence exists suggesting that IFN-c could alter airway
remodeling [15–18], but the involved molecular mechanisms are
not known in detail. Concerning the fibrotic aspect, in a bleomy-
cin-mouse model of lung fibrosis, IFN-c down-regulated TGF-
b gene expression and suppressed both the proliferation of
fibroblasts and collagen synthesis [36]. A study of various forms
of pulmonary fibrosis, including idiopathic pulmonary fibrosis,
indicated that there may be a general impairment of the
production of IFN-c in patients with pulmonary fibrosis [37]. In
patients with idiopathic pulmonary fibrosis, 6-month treatment
with IFN-c and low dose prednisolone has been reported to reduce
the levels of transcription of both TGF-ß1 and CTGF, and to
improve lung function and blood gases [38].
Concerning the vessels, IFN-c can attenuate angiogenesis
during wound healing [39–42]. Although an endogenous anti-
angiogenic activity of IFN-c has been described, the mechanism
by which IFN-c regulates angiogenesis is not well understood.
According to our finding of an anti-proliferative effect of IFN-c on
LEC, anti-angiogenic effects of IFN-c were previously described in
Figure 6. Additive effect of IFN-c and TNF-a on the inhibition of LEC proliferation. Proliferation was assessed 5 days after the addition of
TNF-a (A), IFN-c (B), or TNF-a + IFN-c (C) at the indicated concentration. Values are means6 SEMs for 3 replicate experiments. Significant differences
(p,0.05) compared with untreated cells are marked by *, compared with INF-c or TNF-a are marked with #.
doi:10.1371/journal.pone.0045430.g006
Figure 7. Effect of CTGF shRNA on basal and TGF-b1 mediated induction of CTGF mRNA- and protein-expression in LEC. A. Effect on
CTGF mRNA level: Four days after downregulation of CTGF by specific shRNA LEC were cultured in serum reduced medium (2% FCS) for 24 h before
treatment with TGF-ß1. RNA and protein was isolated after 24 h of incubation with 10 ng/ml TGF-ß1. CTGF RNA expression, compared to b-actin as
control, was detected by RT-PCR (A). B. Effect on CTGF protein level: CTGF and ß-actin expression on protein level was detected by western
immunoblotting (B). Significant regulations of CTGF by TGF-ß1 are marked by * (p,0.05), CTGF down-regulation by CTGF specific shRNA compared
to control cells are marked by # (p,0.05).
doi:10.1371/journal.pone.0045430.g007
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endothelial cells in other tissues such as the lung [43]. IFN-c
caused growth inhibition and disrupted tube formation of human
umbilical vein endothelial cells (HUVEC) [40]. These effects were
also mediated by Stat1 [40], in agreement with our findings of
IFN-c influence on CTGF expression. Friesel et al. found that
IFN-c inhibits endothelial cell growth factor (ECGW)-induced cell
proliferation of HUVEC with a concomitant change in endothelial
cell morphology [43]. Furthermore, they demonstrated that the
effects of IFN-c on ECGF-induced proliferation correlated with
a decrease in the number of ECGF receptors on the endothelial
cell surface [43].
Besides the direct action of IFN-c on endothelial cells, other
studies provided evidence that IFN-c indirectly mediates its
angiostatic effect. IFN-c could block or attenuate gene expression
of several other known regulators of endothelial cell activation and
angiogenesis, such as the induction of the angiostatic protein IP-10
(interferon-inducible protein-10) [44]. IFN-c suppressed also
VEGF-induced up-regulation of the angiogenetic protein angio-
poetin-2 (Ang-2) or of the VEGF receptor VEGFR2 [40]. This
suggests that up-regulation of angiostatic- or down-regulation of
angiogenic-molecules by IFN-c can be responsible for the anti-
angiogenic activity of IFN-c and influence the balance of
angiogenic molecules in favor of the non angiogenic state. In
relation to these observations, we found that IFN-c can down-
regulate CTGF expression in LEC.
Down-regulation of CTGF by IFN-c has already been de-
scribed by Fitzner et al. in pancreatic stellate cells (PCSs) and was
also Stat1-dependent [45]. Also in keloid-derived fibroblasts and in
rat kidney tubular epithelial cells (NRK52E) IFN-c can reduce
CTGF expression [46,47]. Opposite effects of TGF-b and IFN-c
on trans-differentiation of myofibroblasts in human gingival cell
cultures, with inhibition of CTGF expression by IFN-c, was
described by Sobral et al. [48]. However, no effect of IFN-c on
CTGF expression was found in cultured mesangial cells [49],
which would suggest a cell type specific effect of IFN-c on CTGF
expression.
TGF-b is widely accepted as the most potent inducer of CTGF
[8], while TNF-a was found to suppress CTGF expression in
different cell types like bovine aortic endothelial cells or airway
smooth muscle cells [29–31]. Our results confirmed CTGF
inhibition by TNF-a also in LEC.
Beside a suppression of CTGF expression by TNF-a and IFN-c
alone in LEC, we could detect a new additive effect of IFN-c and
TNF-a co-administration on CTGF inhibition and on LEC-
proliferation inhibition. Many genes which are regulated by IFN-c
are also regulated by TNF-a. Very often the induction was then
synergistic, as described in the study by Stewart et al. [50].
Vascular endothelial platelet endothelial adhesion molecule-1
(PECAM-1) expression was synergistically reduced by TNF-a and
INF-c in endothelial cells [50]. In addition, endothelial cells
treated simultaneously with TNF-a and IFN-c demonstrated
synergistic increases in the synthesis of the angiostatic CXCR3
chemokine compared with cells treated with TNF-a and IFN-c
alone [51]. Also a synergistic inhibition of proliferation of
endothelial cells was observed when TNF-a and IFN-c were
simultaneously added to endothelial cells [51]. Furthermore, an
additive effect of TNF-a and IFN-c on the CXCL10 (IFN-c-
inducible protein-10 (IP-10)) expression in airway smooth muscle
cells could be described [52]. It was postulated that the synergism
between TNF-a and INF-c involved an interaction between the
TNF-a activated NF-kB signaling pathway and the transcription
factors induced by IFN-c like IRF-1 (interferon regulatory factor-
1) [53]. Promotors of genes regulated by IFN-c and TNF-a contain
both an interferon-stimulated response element (ISRE) and an NF-
Figure 8. Effect of CTGF silencing on the proliferation of LEC and IFN-c and TNF-amediated inhibition. A. Proliferation of LEC, in which
CTGF was down-regulated by CTGF shRNA transfection (right side; ‘‘CTGF shRNA’’) and of control cells, which were transfected with non-specific
scrambled shRNA (left side; ‘‘control shRNA’’), was assessed after the addition of 100 ng/ml rCTGF with or without the addition of IFN-c (500 U/ml) at
72 h. Values are means 6 SEMs for 3 replicate cultures. Significant differences to response to rCTGF are marked by * (p,0.05), significant differences
of proliferation between CTGF shRNA and non-specific scrambled shRNA transfected cells are marked by # (p,0.05), and significant differences of
proliferation between CTGF-induced proliferation and CTGF-induced proliferation with the addition of IFN-c are marked by $ (p,0.05). B.
Proliferation of LEC, in which CTGF was down-regulated by CTGF shRNA transfection (lined column; ‘‘CTGF shRNA’’) and of control cells, transfected
with non-specific scrambled shRNA (white column; ‘‘control shRNA’’), was assessed 5 days after the addition of TNF-a (20 ng/ml), IFN-c (500 U/ml), or
TNF-a+IFN-c. Values are means 6 SEMs for 3 replicate experiments and present as % compared with non stimulated cells (100%; black column).
Significant differences between TNF-a and/or IFN-c treated cells to control cells are marked by * (p,0.05).
doi:10.1371/journal.pone.0045430.g008
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kB-site. Cooperation of IFN-c and TNF-a on CTGF inhibition in
LEC and inhibition of LEC proliferation confirmed the relation-
ship between these cytokines also in airway remodeling processes,
as already described in other systems [41].
To study the functional effect of the downregulation of CTGF
in LEC, HPMEC cells were stable transfected with CTGF specific
shRNAs by a lentiviral system. Downregulation of CTGF could be
shown at the RNA- and protein-level. CTGF silencing inhibited
LEC proliferation, indicating that CTGF expression is also
a crucial component for LEC proliferation. Proliferation of lung
and dermal fibroblasts was also suppressed after CTGF-silencing
[54,55]. However, CTGF-silencing in LEC had no effect on IFN-c
induced Stat1 phosphorylation (data not shown) and the anti-
proliferative effect of IFN-c and TNF-a. Therefore, IFN-c and
TNF-a mediated CTGF inhibition was not responsible for the
anti-proliferative effect described for IFN-c and TNF-a.
Our data demonstrated that CTGF was negatively regulated by
IFN-c in LEC in a Jak/Stat signaling pathway-dependent manner.
Down-regulation of the angiogenic molecule CTGF by IFN-c
could be responsible for the described anti-angiogenic activity of
IFN-c and influence the balance of angiogenic molecules in favor
of the non angiogenic state. In addition, we found an additive
effect of IFN-c and TNF-a on CTGF inhibition, which underlines
the relationship between these cytokines also in airway remodeling
processes. The inverse correlation between IFN-c and CTGF
expression in LEC could mean that screwing the Th2 response to
a Th1 response with IFN-c production might be beneficial to
avoid airway remodeling in asthma. Understanding the mechan-
isms involved in regulation of CTGF in LEC and downstream
events mediated by CTGF could provide new therapeutic
strategies for the treatment of special components of asthma, not
addressed yet using the current therapeutic regimens.
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